Dolby Laboratories (DLB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently ma ...
Q1 2025 Earnings Call Transcript January 29, 2025 Dolby Laboratories, Inc. beats earnings expectations. Reported EPS is $1.14 ...
CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...
Dolby Laboratories Inc (DLB) reports a 13% revenue increase, fueled by robust licensing performance and expanding automotive ...
We currently have no DLB Stock Split History on this stock.
San Francisco-based Dolby Labs has reported that its Q1 revenues were $357 million (€343.8m), a significant 13 per cent ...
H.C. Wainwright & Co. is acting as the exclusive financial advisor to SeaStar Medical in connection with the offering.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback